<?xml version="1.0" encoding="UTF-8"?>
<p>In 1 recent publication, early (day 0–28) and late (day 29–90) infectious complications were seen in 30% (14 of 47) and 21% (9 of 43) of patients with ALL who underwent CAR T-cell therapy, respectively [
 <xref rid="CIT0023" ref-type="bibr">23</xref>]. Although a direct comparison was limited by differences in methods and periods of observation, the types of infections occurring in the early and late periods after CTI were similar to those in our study, and life-threatening or fatal infections were also rare.
</p>
